GURBF:OTCMKTS
Guerbet SA
0.00%
(0.00) 1D
දුරුතු 7, 01.19.10 ග්රිමවේ-4 · USD
search
සියලු සංකේත
1D
5D
1M
6M
YTD
1Y
5Y
උපරි
| සංකේතය | මිල | වෙනස් කිරීම | % වෙනස |
|---|
insights_autoGURBF සඳහා ඉහළම ඇතුළාන්තයන් උත්පාදනය කරමින්...
වෙ.පො ප්රාග්ධනය
මි152.70
හඬ පරිමාණය
0.00
සේවකයින් ගණන
ද3
පුවත් සහ කථා
වෙබය හරහා මූලාශ්ර වෙතින්
Simply Wall Street
·
මිනිත්තු 20කට පෙර
Applied Optoelectronics Expands U.S. Footprint To Ride AI Photonics Wave
Morningstar Canada
·
මිනිත්තු 24කට පෙර
iShares Edge S&P 500 Minimum Volatility Offers a Smoother Ride Through US Stock Markets
Benzinga
·
මිනිත්තු 28කට පෙර
Stock Market Today: S&P 500 Futures Drop, Dow Gains As Trump Floats 'New' Iran Proposal—IBM, Bed Bath & B
MarketBeat
·
මිනිත්තු 36කට පෙර
Nayax Ltd. (NASDAQ:NYAX) Given Consensus Recommendation of "Hold" by Brokerages
පැතිකඩ
Guerbet is a France-based manufacturer of contrast agents used in medical imaging. The company was founded in 1926 by André Guerbet, the son of Marcel Guerbet who in 1901 discovered Lipiodol – the first iodinated X-ray contrast agent.
In 2017 Guerbet’s revenues were €807.1 million. It employs over 2,700 people worldwide and has manufacturing facilities in France, Ireland, Canada, Macedonia, the United States and Brazil. The company’s headquarters, formerly located in Villepinte, is currently located in Chicago, and its shares are included in the NASDAQ stock index.
In July 2015, Guerbet announced the takeover of a portion of Mallinckrodt's contrast media and application systems divisions. The acquisition was completed in November 2015.
In 2022, the United States Food and Drug Administration approved Guerbet Group's Elucirem, an MRI contrast agent. The product will be produced at Guerbet's factory in Raleigh, North Carolina and at three of its French factories.
An analysis of the growing global contrast media market, valued at $6.19 billion 2023 US dollars described Guerbet as a "key player." Wikipedia
Guerbet SA ගැන
AI අන්තර්ගතයේ වැරදි ඇතුළත් විය හැක. තව දැන ගන්න